Purple Biotech (PPBT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.65M
Last updated: Nov 17, 2026 at 11:03 AM ET
Purple Biotech (PPBT) Financials: Revenue, Profit and Cash Flow
Purple Biotech reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$26.39M, operating cash flow was -$5.54M and free cash flow was -$5.54M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of $441.00K.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $27.46M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $195.80K | N/A | -0.1% | -11374.1% | -10153.0% |
| Dec 2022 | -$910.00K | N/A | N/A | N/A | N/A |
| Dec 2021 | -$320.00K | -132.0% | N/A | N/A | N/A |
| Dec 2020 | $1.00M | 0.0% | -23.7% | -1333.2% | -2819.5% |
| Dec 2019 | $1.00M | 0.0% | 100.0% | -715.6% | -585.0% |
| Dec 2018 | $1.00M | +900.0% | 100.0% | -782.6% | -520.0% |
| Dec 2017 | $100.00K | N/A | 100.0% | -11966.0% | -12177.0% |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $195.80K | -$910.00K | -$320.00K | $1.00M | $1.00M | $1.00M | $100.00K | N/A |
| Cost of revenue | $204.61K | $186.00K | $196.00K | $120 | $55 | $236.65K | $80 | N/A | N/A | N/A |
| Gross profit | -$204.61K | -$186.00K | -$196 | -$120 | -$55 | -$236.65K | $999.92K | $1.00M | $100.00K | N/A |
| Research and development | $3.73M | $7.62M | $17.03M | $16.32M | $11.83M | $7.29M | $2.28M | $5.27M | $4.64M | $4.18M |
| Operating income | -$27.46M | -$11.01M | -$22.27M | -$22.60M | -$17.93M | -$13.33M | -$7.16M | -$7.83M | -$11.97M | -$7.18M |
| Net income | -$26.39M | -$7.24M | -$19.88M | -$21.67M | -$18.38M | -$28.20M | -$5.85M | -$5.20M | -$12.18M | -$12.13M |
| EBITDA | -$26.25M | -$7.05M | -$19.72M | -$21.49M | -$17.52M | -$13.10M | -$6.14M | -$5.55M | N/A | -$7.04M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | N/A | -$64.82K | -$53.33K | -$58.27K | -$48.01K | -$44.77K | -$40.00K | -$49.00K | -$49.00K | N/A | -$48.52K | -$50.00K |
| Operating income | -$1.30M | -$2.25M | -$23.45M | -$1.37M | -$1.24M | -$1.41M | -$1.02M | -$2.13M | -$3.46M | -$4.47M | -$6.33M | -$5.75M |
| Net income | $441.00K | -$86.00K | -$23.55M | -$1.30M | -$1.08M | -$453.00K | -$410.00K | -$663.00K | -$2.40M | -$3.76M | -$4.88M | -$5.04M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $244.00K by $8.47M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $17.57M | $37.04M | $44.30M | $54.62M | $70.20M | $83.80M | $14.72M | $14.72M | $14.18M | $14.91M |
| Current assets | $9.87M | $8.91M | $15.79M | $33.26M | $48.47M | $59.28M | $8.30M | $8.51M | $7.98M | $14.90M |
| Cash and equivalents | $8.72M | $7.40M | $14.49M | $15.03M | $10.89M | $11.25M | $4.38M | $5.16M | $3.95M | $6.76M |
| Total liabilities | $7.91M | $4.13M | $10.01M | $7.52M | $5.09M | $4.05M | $3.86M | $3.72M | $5.59M | $1.53M |
| Short-term debt | $244.00K | $183.00K | $188.00K | $194.00K | $199.00K | $207.00K | $195.00K | N/A | $1.75M | N/A |
| Shareholder equity | $9.71M | $32.86M | $34.21M | $46.91M | $64.83M | $79.39M | $10.42M | $10.52M | $7.31M | $13.38M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $14.17M | $14.42M | $17.57M | $39.06M | $34.38M | $35.59M | $37.04M | $35.10M | $36.06M | $39.86M | $44.30M | $45.27M |
| Total liabilities | $1.95M | $4.75M | $7.91M | $6.25M | $2.33M | $2.90M | $4.13M | $5.64M | $6.69M | $8.77M | $10.01M | $6.55M |
| Cash and equivalents | $5.24M | $5.57M | $8.72M | $9.59M | $4.74M | $5.77M | $7.40M | $5.44M | $6.52M | $9.98M | $14.49M | $15.10M |
| Shareholder equity | $12.27M | $9.72M | $9.71M | $32.77M | $32.01M | $32.65M | $32.86M | $29.41M | $29.32M | $31.02M | $34.21M | $38.60M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.54M | -$14.37M | -$19.93M | -$16.73M | -$15.25M | -$12.09M | -$5.58M | -$8.48M | -$8.63M | -$6.26M |
| Capital expenditures | $3.02K | $0 | $3.00K | $228.00K | $115.00K | $156.00K | $11.00K | $16.00K | $13.00K | $10.00K |
| Free cash flow | -$5.54M | -$14.37M | -$19.93M | -$16.96M | -$15.37M | -$12.25M | -$5.59M | -$8.50M | -$8.64M | -$6.27M |
| Investing cash flow | $449.54K | $509.00K | $13.88M | $19.91M | $13.41M | -$49.59M | -$449.00K | $2.04M | $2.77M | -$7.91M |
| Financing cash flow | $6.41M | $6.77M | $5.45M | $1.11M | $1.51M | $68.49M | $5.23M | $7.79M | $3.00M | $10.42M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.50M | -$3.12M | -$1.07M | -$1.07M | -$1.54M | -$1.98M | -$2.01M | -$3.29M | -$3.98M | -$5.08M | -$4.98M | -$3.66M |
| Capital expenditures | $0 | $0 | $1.04M | $1.01M | $2.01K | $1.95M | $0 | $0 | $0 | $0 | $0 | $1.00K |
| Free cash flow | -$2.50M | -$3.12M | -$2.11M | -$2.08M | -$1.55M | -$3.93M | -$2.01M | -$3.29M | -$3.98M | -$5.08M | -$4.98M | -$3.66M |
Frequently Asked Questions About PPBT
What is Purple Biotech's annual revenue?
Purple Biotech reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Purple Biotech profitable?
No. Purple Biotech reported net income of -$26.39M for the fiscal year ended Dec 31, 2025.
How much free cash flow does PPBT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.54M minus capital expenditures of $3.02K produced free cash flow of -$5.54M.
How much debt does Purple Biotech have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $244.00K and cash and equivalents of $8.72M.
PPBT pages: Overview, Earnings, Forecast, Financials, Competitors